NCT02320656

Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 650 (estimated)
• Sponsor: Institut Paoli-Calmettes · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

HEMATO-BIO-IPC-2013-015 is a monocenter prospective longitudinal study. Our aim is to define predictive clinical and biological factors in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by using genomics, genetics and epigenetics, in vitro and in vivo drug sensitivity studies,and translational immonulogy and immunomonitoring studies. HEMATO-BIO primary outcome measure is to identify molecular, genomic and epigenetic, pharmacologic and immunophenotypic alteration in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by collecting, at diagnosis and/or complete remission and/or relapse: * tumor samples: marrow aspiration, blood sampling. * non-tumor samples: skin biopsy, buccal swab . from 650 patients treated at our cancer center.

Conditions

• Acute Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Disorders

Interventions

Type	Name	Description
OTHER	Blood sampling	Longitudinal (3 stages of the disease)
OTHER	Bone marrow aspirate	Longitudinal (3 stages of the disease)
OTHER	Skin biopsy	Single biopsy (optional)
OTHER	Buccal swab	Single sampling.

Timeline

• Start date: 2014-05-01
• Primary completion: 2019-05-01
• Completion: 2024-05-01
• First posted: 2014-12-19
• Last updated: 2018-07-26

Locations

1 site across 1 country: France